Phase 1 Trial of THC Softgels: Safe up to 20 mg Daily but Better Tolerated After First Day | Research

The takeaway

A Phase 1 trial of THC-dominant softgels (5-20 mg THC daily) in 41 healthy adults found all adverse events were mild to moderate, with most occurring on the first day. Subjective effects were noticeable only at the highest dose.

Physicians dosing medical THC; pharmacologists; patients beginning THC-based medical cannabis.

30 of 65 adverse events occurred on the first treatment day

What the researchers found

All 65 adverse events were mild-to-moderate; none were serious. Most adverse events (30/65) occurred on the first treatment day, suggesting tolerance develops quickly. At the highest dose (20 mg THC daily), participants reported feeling "any effect" and "dazed" compared to placebo. The recommended starting dose was 10 mg THC daily.

Why it matters

Like its companion CBD study, this provides pharmaceutical-grade dosing data for THC. The finding that most side effects occur on Day 1 and then improve supports the clinical practice of starting low and titrating slowly.

The numbers in context

41 participants. Doses: 5-20 mg THC daily. All 65 AEs mild-moderate. Most common: somnolence (8), lethargy (7), headache (5). 30/65 AEs on first day. Subjective effects ("feel any effect," "dazed") significantly different from placebo only at 20 mg. Recommended start: ≤10 mg THC daily.

How the study worked

Phase 1, multiple-dose, randomized, placebo-controlled study. 41 healthy participants received one of four THC doses (5-20 mg/day with minimal CBD) or placebo, administered every 12 hours with food for 7 days. Safety, plasma drug levels, and self-reported subjective effects were measured.

What this study cannot tell us

Healthy participants only, short 7-day duration. The THC doses tested (5-20 mg) represent the lower end of what some medical cannabis patients use. CBD content was minimal (<0.25 mg/day), so this reflects a THC-dominant profile only.

How to read the evidence

Moderate: randomized, placebo-controlled Phase 1 design, but small sample and healthy participants only.

When this study was published

Published in 2022.

The bigger picture

Together with the companion Spectrum Yellow (CBD-dominant) study, this provides a comprehensive dosing framework for standardized cannabis products. The clear first-day effect followed by tolerance is consistent with clinical experience and supports the "start low, go slow" approach.

Questions still open

How would these results differ in patients with chronic pain or other conditions where THC tolerance may already exist? Does the rapid tolerance to first-day effects extend to therapeutic effects as well?

Common questions

Will THC side effects get better over time?

In this study, most side effects (somnolence, lethargy, headache) occurred on the first day of treatment and decreased after that, suggesting rapid tolerance to acute effects. The recommended approach is to start at 10 mg daily or less and increase gradually.

At what dose does THC cause noticeable effects?

In this study of cannabis-naive healthy adults, subjective effects like feeling "dazed" were only significantly different from placebo at the highest dose of 20 mg THC daily. Lower doses (5-15 mg) did not produce consistent subjective effects.

Read the original research

Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.

Journal of analytical toxicology, 46(5), 528-539

View on PubMed ↗Publisher’s paper ↗

Citation

Peters, Erica N; Mosesova, Irina; MacNair, Laura; Vandrey, Ryan; Land, M Hunter; Ware, Mark A; Turcotte, Cynthia; Bonn-Miller, Marcel O. (2022). Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.. Journal of analytical toxicology, 46(5), 528-539. https://doi.org/10.1093/jat/bkab035